Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population (PsyConfPop)

28. december 2020 opdateret af: University Hospital, Montpellier

Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population : PsyConfPop

Quarantine is an unpleasant experience : separation from loved ones, loss of freedom, uncertainty about infection status, boredom. It may lead to negative mental health consequences and thus the emergence of anxiety and depressive symptoms.

From March 17th, 2020 to May 11th 2002, the French government has implemented national containment measures due to the Covid-19 epidemic.

Although there are data on the psychological impact and experience of quarantine measures in people who have been infected or suspected of being carriers of certain pathogens (e.g. Ebola), there are no data on such impact in the French population and quarantines lasting longer than 21 days. Investigators therefore propose to conduct a human and social sciences study in order to better understand the current situation

Studieoversigt

Status

Ukendt

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The main objective is to describe the psychological state during confinement (and the impact of the confinement) in a sample of the French general population.

Secondary objectives :

  • to assess the evolution of psychological health between the period of confinement and post-confinement.
  • to identify clinical factors modulating psychological state during confinement

It is expected to highlight :

  • a link between the intensity of anxiety symptoms and the number/quality of social contacts
  • a reduction of anxiety and depression symptoms in the post-confinement period.
  • higher consumption of drugs during the confinement period

Self-questionnaires (Google form format) are sent by mailing lists or social networks to participants in order to complete the assessment of psychological state. A unique identifier is sent in a separate email. These assessments are performed at least once during the confinement period. It is planned to repeat them when the confinement is lifted: 15 days, 3 and 6 months after the lifting of the confinement because of the risk of developing anxiodepressive symptoms, in particular post-traumatic stressors.

Undersøgelsestype

Observationel

Tilmelding (Forventet)

500

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Frankrig
      • Montpellier, Frankrig, 34295
        • Rekruttering
        • University Hospital
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

Adults who agree to participate by answering the questionnaires

Beskrivelse

Inclusion criteria:

- age> 18

Exclusion criteria:

- protective measure (curatorship, guardianship)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Confined patients
General population
Andet: Slef questionnaires fulfilment
Questionnaires to assess the psychological impact of confinement and its evolution over 6 months

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Depressive Symptomatology
Tidsramme: during confinement
depressive symptomatology with Patient Health Questionnaire : PHQ-9 scale (PHQ 9 higher score, more depressive -> min : 0 max : 27)
during confinement

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Depressive Symptomatology
Tidsramme: post-confinement : 15 days, 3 months, 6 months
depressive symptomatology with Patient Health Questionnaire : PHQ-9 scale (PHQ 9 higher score, more depressive -> min : 0 max : 27)
post-confinement : 15 days, 3 months, 6 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Psychological pain
Tidsramme: during confinement
Psychological pain : likert scale (higher score, more psychological pain-> min : 0 max : 10)
during confinement
sleep
Tidsramme: during confinement
quality of sleep assessed with Insomnia Seveity Index (ISI Insomnia Severity Scale ; higher score, more insomnia -> min : 0 max : 28)
during confinement
sleep
Tidsramme: post-confinement (15 days, 3 months, 6 months)
quality of sleep assessed with Insomnia Seveity Index (ISI Insomnia Severity Scale ; higher score, more insomnia -> min : 0 max : 28)
post-confinement (15 days, 3 months, 6 months)
anxiety
Tidsramme: during confinement
anxiety intensity assessed by Generalized Anxieety Disorder (GAD 7 Generalized Anxiety Disorder higher score, more anxious -> min : 0 max : 21)
during confinement
anxiety
Tidsramme: post-confinement (15 days, 3 months, 6 months)
anxiety intensity assessed by Generalized Anxieety Disorder (GAD 7 Generalized Anxiety Disorder higher score, more anxious -> min : 0 max : 21)
post-confinement (15 days, 3 months, 6 months)
psychological pain
Tidsramme: post-confinement (15 days, 3 months, 6 months)
psychological pain : likert scale (higher score, more psychological pain-> min : 0 max : 10)
post-confinement (15 days, 3 months, 6 months)
physical pain
Tidsramme: during confinement
psychological pain : likert scale (higher score, more psychological pain-> min : 0 max : 10)
during confinement
physical pain
Tidsramme: post-confinement (15 days, 3 months, 6 months)
psychological pain : likert scale higher score, more psychological pain-> min : 0 max : 10)
post-confinement (15 days, 3 months, 6 months)
anger
Tidsramme: during confinement
staxi state scale (STAXI ; State and Trait Anger Expression Inventory : higher score, more anger -> min : 0 max : 50)
during confinement
anger
Tidsramme: post-confinement (15 days, 3 months, 6 months)
staxi state scale (STAXI ; State and Trait Anger Expression Inventory : higher score, more anger -> min : 0 max : 50)
post-confinement (15 days, 3 months, 6 months)
Stressful Event Impact
Tidsramme: during confinement

Assessed by the Stressful Event Impact Scale - Horowitz (HOROWITZ higher score, more traumatizes -> min : 0 max : 45)

)
during confinement
Stressful Event Impact
Tidsramme: post-confinement (15 days, 3 months, 6 months)
Assessed by the Stressful Event Impact Scale - Horowitz (HOROWITZ higher score, more traumatizes -> min : 0 max : 45)
post-confinement (15 days, 3 months, 6 months)
Use of psychotropic drugs
Tidsramme: during confinement
Number of patients declaring an increase of psychotropic drug use
during confinement
Use of psychotropic drugs
Tidsramme: post-confinement (15 days, 3 months, 6 months)
Number of patients declaring an increase of psychotropic drug use
post-confinement (15 days, 3 months, 6 months)
Tobacco consumption
Tidsramme: during confinement
Number of patients declaring an increase of tobacco consumption
during confinement
Tobacco consumption
Tidsramme: post-confinement (15 days, 3 months, 6 months)
Number of patients declaring an increase of tobacco consumption
post-confinement (15 days, 3 months, 6 months)
alcohol consumption
Tidsramme: post-confinement (15 days, 3 months, 6 months)
Number of patients declaring an increase of alcohol consumption
post-confinement (15 days, 3 months, 6 months)
alcohol consumption
Tidsramme: confinement
Number of patients declaring an increase of alcohol consumption
confinement
Illicit substances consumption
Tidsramme: confinement
Number of patients declaring an increase of illicit substances consumption
confinement
Illicit substances consumption
Tidsramme: post-confinement (15 days, 3 months, 6 months)
Number of patients declaring an increase of illicit substances consumption
post-confinement (15 days, 3 months, 6 months)
orientation of life
Tidsramme: confinement
Life Orinetation Test Revised (LOT-R questionnaire): higher score, more optimistic --> min : 0 max : 24
confinement
orientation of life
Tidsramme: post-confinement (15 days, 3 months, 6 months)
Life Orinetation Test Revised (LOT-R questionnaire): higher score, more optimistic --> min : 0 max : 24
post-confinement (15 days, 3 months, 6 months)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University Hospital, Montpellier

Efterforskere

  • Ledende efterforsker: Emilie OLIE, MD PhD, University Hospital, Montpellier

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. april 2020

Primær færdiggørelse (Forventet)

1. december 2021

Studieafslutning (Forventet)

30. december 2021

Datoer for studieregistrering

Først indsendt

30. april 2020

Først indsendt, der opfyldte QC-kriterier

30. april 2020

Først opslået (Faktiske)

5. maj 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. december 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. december 2020

Sidst verificeret

1. december 2020

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • RECHMPL20_0197

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

NC

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Depression

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Oman

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner